Early osteoblastic differentiation induced by dexamethasone enhances adenoviral gene delivery to marrow stromal cells

Jeremy S. Blum, M. Brandon Parrott, Antonios G. Mikos, Michael A Barry

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We investigated the implications of induced osteogenic differentiation on gene delivery in multipotent rat marrow stromal cells (MSCs). Prior to genetic manipulation cells were cultured with or without osteogenic supplements (5 × 10-8 M dexamethasone, 160 μM l-ascorbic acid 2-phosphate, and 10 mM β-glycerophosphate). Comparison of liposome, retroviral, and adenoviral vectors demonstrated that all three vectors could mediate gene delivery to primary rat MSCs. When these vectors were applied in the absence or presence of osteogenic supplements, we found that MSCs differentiated prior to transduction with adenovirus type 5 vectors produced a 300% increase in transgene expression compared to MSCs that were not exposed to osteogenic supplements. This differentiation effect appeared specific to adenoviral mediated gene delivery, since there was minimal increase in retroviral gene delivery and no increase in liposome gene delivery when MSCs were treated with osteogenic supplements. In addition, we also determined this increase in transgene production to occur at a higher concentration of dexamethasone (5 × 10-8 M) in the culture medium of MSCs prior to adenoviral transduction. We found that this increased transgene production could be extended to the osteogenic protein, human bone morphogenetic protein 2 (hBMP-2). When delivered by an adenoviral vector, hBMP-2 transgene production could be increased from 1.4 ng/105 cells/3 days to 4.3 ng/105 cells/3 days by culture of MSCs with osteogenic supplements prior to transduction. These results indicate that the utility of MSCs as a therapeutic protein delivery mechanism through genetic manipulation can be enhanced by pre-culture of these cells with dexamethasone.

Original languageEnglish (US)
Pages (from-to)411-416
Number of pages6
JournalJournal of Orthopaedic Research
Volume22
Issue number2
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Stromal Cells
Dexamethasone
Bone Marrow
Transgenes
Genes
Liposomes
Glycerophosphates
Adenoviridae
Culture Media
Cultured Cells
Proteins
Cell Culture Techniques

Keywords

  • Dexamethasone
  • Gene therapy
  • hBMP-2
  • Marrow stromal cells
  • Osteodifferentiation

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Early osteoblastic differentiation induced by dexamethasone enhances adenoviral gene delivery to marrow stromal cells. / Blum, Jeremy S.; Parrott, M. Brandon; Mikos, Antonios G.; Barry, Michael A.

In: Journal of Orthopaedic Research, Vol. 22, No. 2, 2004, p. 411-416.

Research output: Contribution to journalArticle

@article{9b6119afb14d4a1b9fc156a5cb1b4772,
title = "Early osteoblastic differentiation induced by dexamethasone enhances adenoviral gene delivery to marrow stromal cells",
abstract = "We investigated the implications of induced osteogenic differentiation on gene delivery in multipotent rat marrow stromal cells (MSCs). Prior to genetic manipulation cells were cultured with or without osteogenic supplements (5 × 10-8 M dexamethasone, 160 μM l-ascorbic acid 2-phosphate, and 10 mM β-glycerophosphate). Comparison of liposome, retroviral, and adenoviral vectors demonstrated that all three vectors could mediate gene delivery to primary rat MSCs. When these vectors were applied in the absence or presence of osteogenic supplements, we found that MSCs differentiated prior to transduction with adenovirus type 5 vectors produced a 300{\%} increase in transgene expression compared to MSCs that were not exposed to osteogenic supplements. This differentiation effect appeared specific to adenoviral mediated gene delivery, since there was minimal increase in retroviral gene delivery and no increase in liposome gene delivery when MSCs were treated with osteogenic supplements. In addition, we also determined this increase in transgene production to occur at a higher concentration of dexamethasone (5 × 10-8 M) in the culture medium of MSCs prior to adenoviral transduction. We found that this increased transgene production could be extended to the osteogenic protein, human bone morphogenetic protein 2 (hBMP-2). When delivered by an adenoviral vector, hBMP-2 transgene production could be increased from 1.4 ng/105 cells/3 days to 4.3 ng/105 cells/3 days by culture of MSCs with osteogenic supplements prior to transduction. These results indicate that the utility of MSCs as a therapeutic protein delivery mechanism through genetic manipulation can be enhanced by pre-culture of these cells with dexamethasone.",
keywords = "Dexamethasone, Gene therapy, hBMP-2, Marrow stromal cells, Osteodifferentiation",
author = "Blum, {Jeremy S.} and Parrott, {M. Brandon} and Mikos, {Antonios G.} and Barry, {Michael A}",
year = "2004",
doi = "10.1016/j.orthres.2003.08.006",
language = "English (US)",
volume = "22",
pages = "411--416",
journal = "Journal of Orthopaedic Research",
issn = "0736-0266",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Early osteoblastic differentiation induced by dexamethasone enhances adenoviral gene delivery to marrow stromal cells

AU - Blum, Jeremy S.

AU - Parrott, M. Brandon

AU - Mikos, Antonios G.

AU - Barry, Michael A

PY - 2004

Y1 - 2004

N2 - We investigated the implications of induced osteogenic differentiation on gene delivery in multipotent rat marrow stromal cells (MSCs). Prior to genetic manipulation cells were cultured with or without osteogenic supplements (5 × 10-8 M dexamethasone, 160 μM l-ascorbic acid 2-phosphate, and 10 mM β-glycerophosphate). Comparison of liposome, retroviral, and adenoviral vectors demonstrated that all three vectors could mediate gene delivery to primary rat MSCs. When these vectors were applied in the absence or presence of osteogenic supplements, we found that MSCs differentiated prior to transduction with adenovirus type 5 vectors produced a 300% increase in transgene expression compared to MSCs that were not exposed to osteogenic supplements. This differentiation effect appeared specific to adenoviral mediated gene delivery, since there was minimal increase in retroviral gene delivery and no increase in liposome gene delivery when MSCs were treated with osteogenic supplements. In addition, we also determined this increase in transgene production to occur at a higher concentration of dexamethasone (5 × 10-8 M) in the culture medium of MSCs prior to adenoviral transduction. We found that this increased transgene production could be extended to the osteogenic protein, human bone morphogenetic protein 2 (hBMP-2). When delivered by an adenoviral vector, hBMP-2 transgene production could be increased from 1.4 ng/105 cells/3 days to 4.3 ng/105 cells/3 days by culture of MSCs with osteogenic supplements prior to transduction. These results indicate that the utility of MSCs as a therapeutic protein delivery mechanism through genetic manipulation can be enhanced by pre-culture of these cells with dexamethasone.

AB - We investigated the implications of induced osteogenic differentiation on gene delivery in multipotent rat marrow stromal cells (MSCs). Prior to genetic manipulation cells were cultured with or without osteogenic supplements (5 × 10-8 M dexamethasone, 160 μM l-ascorbic acid 2-phosphate, and 10 mM β-glycerophosphate). Comparison of liposome, retroviral, and adenoviral vectors demonstrated that all three vectors could mediate gene delivery to primary rat MSCs. When these vectors were applied in the absence or presence of osteogenic supplements, we found that MSCs differentiated prior to transduction with adenovirus type 5 vectors produced a 300% increase in transgene expression compared to MSCs that were not exposed to osteogenic supplements. This differentiation effect appeared specific to adenoviral mediated gene delivery, since there was minimal increase in retroviral gene delivery and no increase in liposome gene delivery when MSCs were treated with osteogenic supplements. In addition, we also determined this increase in transgene production to occur at a higher concentration of dexamethasone (5 × 10-8 M) in the culture medium of MSCs prior to adenoviral transduction. We found that this increased transgene production could be extended to the osteogenic protein, human bone morphogenetic protein 2 (hBMP-2). When delivered by an adenoviral vector, hBMP-2 transgene production could be increased from 1.4 ng/105 cells/3 days to 4.3 ng/105 cells/3 days by culture of MSCs with osteogenic supplements prior to transduction. These results indicate that the utility of MSCs as a therapeutic protein delivery mechanism through genetic manipulation can be enhanced by pre-culture of these cells with dexamethasone.

KW - Dexamethasone

KW - Gene therapy

KW - hBMP-2

KW - Marrow stromal cells

KW - Osteodifferentiation

UR - http://www.scopus.com/inward/record.url?scp=0742319024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742319024&partnerID=8YFLogxK

U2 - 10.1016/j.orthres.2003.08.006

DO - 10.1016/j.orthres.2003.08.006

M3 - Article

C2 - 15013104

AN - SCOPUS:0742319024

VL - 22

SP - 411

EP - 416

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

SN - 0736-0266

IS - 2

ER -